Updated employee announcements, business news and recognition in the industry today.
People
Cliff Echols
SCORR Marketing, a global health science marketing and communications firm, has announced the addition of three employees--Cliff Echols as market intelligence director; and Kerry Hutchings and Cherie Squires as senior directors of program management.
Kerry Hutchings
TFS International, a Sweden-based, global mid-size CRO, has appointed Birgitte Volck, MD, PhD, as a non-executive Director to serve on the Company's Board of Directors. Dr. Volck is the Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline in the UK. Schulman IRB, a central IRB, announced Michele Russell-Einhorn, JD, will join the organization September 1, 2016, as Vice President for Oncology Services. Russell-Einhorn currently is Senior Director of Dana-Farber Cancer Institute’s Office for Human Research Studies. At Schulman IRB, she will build and lead the company’s forthcoming Central Oncology Review (COR) division, launching later in 2016.
Cherie Squires
Business News Dr Rabinder Buttar, founder and CEO of ClinTec International, joined an industry-leading expert panel of judges for the eighth round final of the Scottish EDGE competition, which identifies and supports Scotland’s up-and-coming, innovative, high-growth generating entrepreneurial talent. Recognition Q2 Solutions, a global clinical trials laboratory services organization and joint venture of Quest and Quintiles, has received the 2016 Lilly Global Supplier Award. Q2 Solutions was one of 12 companies to receive the award this year, recognizing the company’s ongoing contributions to Lilly’s drug development efforts. ClinCapture, a provider of free and validated electronic data capture (EDC) software, announced its nomination for a Bronze 2016 Stevie Award by the American Business Awardsâ in the Cloud Application/Service as well as the Software Development Solution Website category.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.